CN114099531A - 一种药物在治疗新型冠状病毒肺炎中的应用 - Google Patents
一种药物在治疗新型冠状病毒肺炎中的应用 Download PDFInfo
- Publication number
- CN114099531A CN114099531A CN202111541575.0A CN202111541575A CN114099531A CN 114099531 A CN114099531 A CN 114099531A CN 202111541575 A CN202111541575 A CN 202111541575A CN 114099531 A CN114099531 A CN 114099531A
- Authority
- CN
- China
- Prior art keywords
- inosine
- cov
- sars
- medicine
- inhibit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 23
- 206010035664 Pneumonia Diseases 0.000 title claims abstract description 22
- 241000711573 Coronaviridae Species 0.000 title claims abstract description 14
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical group O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims abstract description 39
- 229930010555 Inosine Natural products 0.000 claims abstract description 38
- 229960003786 inosine Drugs 0.000 claims abstract description 38
- 108090001005 Interleukin-6 Proteins 0.000 claims abstract description 24
- 238000002347 injection Methods 0.000 claims abstract description 5
- 239000007924 injection Substances 0.000 claims abstract description 5
- 239000007788 liquid Substances 0.000 claims abstract description 5
- 239000002775 capsule Substances 0.000 claims abstract description 4
- 239000000839 emulsion Substances 0.000 claims abstract description 4
- 238000002360 preparation method Methods 0.000 claims abstract description 4
- 241000700605 Viruses Species 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 206010035742 Pneumonitis Diseases 0.000 claims description 2
- 102000004889 Interleukin-6 Human genes 0.000 abstract description 23
- 241001678559 COVID-19 virus Species 0.000 abstract description 18
- 230000004083 survival effect Effects 0.000 abstract description 13
- 210000004072 lung Anatomy 0.000 abstract description 12
- 230000002757 inflammatory effect Effects 0.000 abstract description 9
- 208000028399 Critical Illness Diseases 0.000 abstract description 7
- 208000027418 Wounds and injury Diseases 0.000 abstract description 7
- 230000006378 damage Effects 0.000 abstract description 7
- 208000014674 injury Diseases 0.000 abstract description 7
- 206010052015 cytokine release syndrome Diseases 0.000 description 8
- 230000001276 controlling effect Effects 0.000 description 7
- 206010050685 Cytokine storm Diseases 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 208000030090 Acute Disease Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000025721 COVID-19 Diseases 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical class O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000001749 optic atrophy Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种药物在治疗新型冠状病毒肺炎中的应用，属于生物医学技术领域，其技术方案要点是：药物为肌苷，将肌苷应用于抑制IL‑6水平，从而抑制SARS‑COV‑2；肌苷为片剂、胶囊、口服液体制剂、乳液和注射液中的一种或多种。本发明主要用于降低SARS‑COV‑2诱导的IL‑6的高表达，从而能够有效控制SARS‑CoV‑2导致的肺部炎性损伤，进而大幅提升SARS‑CoV‑2危重症存活率。该药物为重症、危重症新冠肺炎患者及其家庭带来了希望，并为治疗新冠肺炎重症、危重症患者提供了新思路。
Description
技术领域
本发明涉及生物医学技术领域，尤其涉及一种药物在治疗新型冠状病毒肺炎中的应用。
背景技术
肌苷(Inosine)属于最常见次黄嘌呤类核苷酸物质，广泛存在有关动植物机体内，它参与机体的各种生理机能及代谢过程，是一种重要的医药和合成其他药物的原料；在医药工业中，肌苷可加工成注射液、口服液或片剂；肌苷具有良好的细胞膜通透性，能直接进入细胞参与物质代谢，临床上肌苷适用于各种急慢性肝脏疾病、心脏病、白血球或血小板减少症、中心视网膜炎和视神经萎缩等症状。
新型冠状病毒(SARS-COV-2)是一种从未在人体内发现的新型冠状病毒株。它是一种RNA病毒，基因组为单链、线性RNA。病毒颗粒呈圆形或椭圆形，正链RNA意味着病毒进入细胞直接合成蛋白质，并通过RNA聚合酶产生负链进行自我复制。新冠肺炎疫情已经成为一场全球性的大流行，对人类健康和生命产生了重大的不利影响，截至目前，全球已有超过两亿例的累计确诊病例，且仍在一些国家快速传播。
感染SARS-COV-2的许多重症和危重患者经常出现免疫系统的过度反应，对危重症患者的存活率存在重大影响，寻找一种对新冠病毒有抑制作用的药物具有重要意义。
为了解决上述问题，在现有技术的基础上提供了一种药物在治疗新型冠状病毒肺炎中的应用。
发明内容
本发明的目的是提供一种药物在治疗新型冠状病毒肺炎中的应用，该药物能够降低SARS-COV-2诱导的IL-6的高表达，从而能够有效控制SARS-CoV-2导致的肺部炎性损伤，进而大幅提升SARS-CoV-2危重症存活率。该药物为重症、危重症新冠肺炎患者及其家庭带来了希望，并为治疗新冠肺炎重症、危重症患者提供了新思路。
本发明的上述技术目的是通过以下技术方案得以实现的：
一种药物在治疗新型冠状病毒肺炎中的应用，所述药物为肌苷，将所述肌苷应用于抑制IL-6水平，从而抑制新冠肺炎病毒(SARS-COV-2)。
进一步地：所述肌苷为片剂、胶囊、口服液体制剂、乳液和注射液中的一种或多种。
通过上述技术方案，肌苷可降低自身免疫性疾病、癌症或过敏性肺炎等疾病的炎性因子水平，抑制巨噬细胞、淋巴细胞和中性粒细胞的活化，从而改善肠道和肺损伤。且肌苷能通过细胞因子风暴调控，从而改善重症或危重症COVID-19的存活率。
肌苷能够减轻SARS-COV-2诱导的肺脏组织病理学变化、抑制细胞因子IL-6的分泌。在SARS-CoV-2诱导的细胞因子风暴(CRS)过程中，IL-6是最关键的细胞因子之一，其严重程度与IL-6的升高密切相关，因此，控制IL-6有助于控制细胞因子风暴，肌苷能够抑制SARS-COV-2诱导的IL-6的高表达，从而能够有效控制SARS-CoV-2导致的肺部炎性损伤，进而大幅提升SARS-CoV-2危重症存活率。
综上所述，本发明具有以下有益效果：
1.该药物能够降低SARS-COV-2诱导的IL-6的高表达，从而能够有效控制SARS-CoV-2导致的肺部炎性损伤，进而大幅提升SARS-CoV-2危重症存活率。
2.该药物为重症、危重症新冠肺炎患者及其家庭带来了希望，并为治疗新冠肺炎重症、危重症患者提供了新思路。
附图说明
图1是本发明实施例的肌苷能提高新冠致死动物模型存活率的实验数据统计图；
图2是本发明实施例的肌苷能促进新冠感染动物体重恢复的实验数据统计图；
图3本发明实施例的肌苷能有效控制并恢复新冠感染动物肺部炎性损伤的实验结果示意图；
图4本发明实施例的肌苷能抑制由SARS-CoV-2诱导的IL-6水平的实验结果示意图。
具体实施方式
下面结合附图和实施方式对本发明作进一步的详细说明：
实施例：一种药物在治疗新型冠状病毒肺炎中的应用，药物为肌苷，将肌苷应用于抑制IL-6水平，从而抑制SARS-COV-2；肌苷为片剂、胶囊、口服液体制剂、乳液和注射液中的一种或多。
肌苷能够大幅提升SARS-CoV-2危重症存活率。本实施例的检测结果如下：
A.肌苷能提高新冠致死动物模型存活率，能促进新冠感染动物体重恢复。
如图1至图2所示，肌苷能够提高小鼠的存活率。研究结果表明，感染SARS-COV-2(model组)的Balb/c小鼠在第4至7天因病毒感染导致多器官炎症而死亡，并且体重下降明显。(Inosine组)预防性服用肌苷后，我们观察到Balb/c小鼠的生存期显著延长，小鼠体重下降幅度较小，并且在感染后第8天体重逐渐回升。
B.肌苷能够减轻SARS-COV-2诱导的小鼠肺脏组织病理学变化。
如图3所示，肌苷能够减轻SARS-COV-2诱导的小鼠肺脏组织病理学变化。通过H&E染色观察肌苷对肺脏组织病理学的影响，结果显示，与空白对照组(Vehicle组)相比，感染SARS-COV-2组(model组)可见点、片状出血，出现大量中性粒细胞浸润，和肺间质水肿现象；而口服肌苷组(Inosine组)的肺组织结构完整，肺泡腔清晰，肺泡壁无充血，炎症浸润现象较SARS-COV-2组有明显的改善。
C.肌苷抑制细胞因子IL-6的分泌。
在细胞因子风暴(CRS)发生过程中，IL-6是最关键的细胞因子之一，其严重程度与IL-6的升高密切相关；在SARS-CoV-2诱导的细胞因子风暴中IL-6亦发挥着重要作用。为了确定肌苷是否能够抑制IL-6的分泌，通过Elisa测定了小鼠血清中细胞因子IL-6的水平。结果表明，肌苷(Inosine组)能够抑制SARS-COV-2诱导的IL-6的高表达，并通过控制IL-6有助于控制细胞因子风暴。
结论：肌苷能通过抑制IL-6水平，有效控制SARS-CoV-2导致的肺部炎性损伤，大幅提升SARS-CoV-2危重症存活率。
在本发明的上述实施例中，该药物能够降低SARS-COV-2诱导的IL-6的高表达，从而能够有效控制SARS-CoV-2导致的肺部炎性损伤，进而大幅提升SARS-CoV-2危重症存活率。该药物为重症、危重症新冠肺炎患者及其家庭带来了希望，并为治疗新冠肺炎重症、危重症患者提供了新思路。
本具体实施例仅仅是对本发明的解释，其并不是对本发明的限制，本领域技术人员在阅读完本说明书后可以根据需要对本实施例做出没有创造性贡献的修改，但只要在本发明的权利要求范围内都受到专利法的保护。
Claims (2)
1.一种药物在治疗新型冠状病毒肺炎中的应用，其特征是：所述药物为肌苷，将所述肌苷应用于抑制IL-6水平，从而抑制新冠肺炎病毒(SARS-COV-2)。
2.根据权利要求1所述的一种药物在治疗新型冠状病毒肺炎中的应用，其特征是：所述肌苷为片剂、胶囊、口服液体制剂、乳液和注射液中的一种或多种。
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111541575.0A CN114099531A (zh) | 2021-12-16 | 2021-12-16 | 一种药物在治疗新型冠状病毒肺炎中的应用 |
| US18/271,296 US20240299436A1 (en) | 2021-12-16 | 2022-03-02 | Use of Inosine in Preparing Drug For Treatment of Corona Virus Disease 2019 |
| PCT/CN2022/078715 WO2023108905A1 (zh) | 2021-12-16 | 2022-03-02 | 肌苷在制备治疗新型冠状病毒肺炎的药物中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111541575.0A CN114099531A (zh) | 2021-12-16 | 2021-12-16 | 一种药物在治疗新型冠状病毒肺炎中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114099531A true CN114099531A (zh) | 2022-03-01 |
Family
ID=80365117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111541575.0A Pending CN114099531A (zh) | 2021-12-16 | 2021-12-16 | 一种药物在治疗新型冠状病毒肺炎中的应用 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20240299436A1 (zh) |
| CN (1) | CN114099531A (zh) |
| WO (1) | WO2023108905A1 (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023108905A1 (zh) * | 2021-12-16 | 2023-06-22 | 中国人民解放军军事科学院军事医学研究院 | 肌苷在制备治疗新型冠状病毒肺炎的药物中的应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021201224A1 (ja) * | 2020-04-02 | 2021-10-07 | 株式会社スタージェン | ミトコンドリア保護剤、ミトコンドリア障害改善剤、またはミトコンドリア機能改善剤 |
| WO2022003531A1 (en) * | 2020-07-01 | 2022-01-06 | Iachettini Giampietro | Modified adenosine nucleoside for use in the treatment of viral infections |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL273843A (en) * | 2020-04-06 | 2021-10-31 | Susan E Lifshitz Patent Attorney Dr | Pharmaceutical compositions for treating corona virus disease covid-19 |
| EP3906922A1 (en) * | 2020-05-07 | 2021-11-10 | 4Living Biotech | New compositions and methods of treating covid-19 disease |
| CN114099531A (zh) * | 2021-12-16 | 2022-03-01 | 中国人民解放军军事科学院军事医学研究院 | 一种药物在治疗新型冠状病毒肺炎中的应用 |
-
2021
- 2021-12-16 CN CN202111541575.0A patent/CN114099531A/zh active Pending
-
2022
- 2022-03-02 WO PCT/CN2022/078715 patent/WO2023108905A1/zh active Application Filing
- 2022-03-02 US US18/271,296 patent/US20240299436A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021201224A1 (ja) * | 2020-04-02 | 2021-10-07 | 株式会社スタージェン | ミトコンドリア保護剤、ミトコンドリア障害改善剤、またはミトコンドリア機能改善剤 |
| WO2022003531A1 (en) * | 2020-07-01 | 2022-01-06 | Iachettini Giampietro | Modified adenosine nucleoside for use in the treatment of viral infections |
Non-Patent Citations (2)
| Title |
|---|
| 劳志刚等: "肌苷减轻严重脓毒症患者炎症反应的临床研究", 《中华危重病急救医学》 * |
| 江磊: "肌苷治疗严重脓毒症35 例疗效评价", 《中国药业》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023108905A1 (zh) * | 2021-12-16 | 2023-06-22 | 中国人民解放军军事科学院军事医学研究院 | 肌苷在制备治疗新型冠状病毒肺炎的药物中的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023108905A1 (zh) | 2023-06-22 |
| US20240299436A1 (en) | 2024-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lian et al. | Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study | |
| Geng et al. | The role of CCL2/CCR2 axis in cerebral ischemia-reperfusion injury and treatment: from animal experiments to clinical trials | |
| JP2006131623A (ja) | 薬剤 | |
| CN114099531A (zh) | 一种药物在治疗新型冠状病毒肺炎中的应用 | |
| CN114028453A (zh) | 广谱抗病毒药物、及其药物组合物和应用 | |
| Bryushkova et al. | Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study | |
| Sheshe et al. | Mechanism of antiviral immune response and COVID-19 infection | |
| Beilharz et al. | Oromucosal administration of interferon to humans | |
| Sugiyama et al. | Effects of long-term administration of erythromycin on cytokine production in rat alveolar macrophages | |
| CN101437534A (zh) | 口服干扰素的广谱免疫和抗病毒基因调节作用 | |
| Zimmermann et al. | A Novel Prophylaxis Strategy Using Liposomal Vaccine Adjuvant CAF09b Protects against Influenza Virus Disease | |
| CN104288168A (zh) | 延龄草苷在制备用于治疗和/或预防小胶质细胞介导的疾病的药物中的用途 | |
| Sun et al. | Mrgprb2 gene plays a role in the anaphylactoid reactions induced by Houttuynia cordata injection | |
| CN114762694B (zh) | 寡糖转移酶抑制剂在预防和/或治疗新型冠状病毒感染中的应用 | |
| KR102428553B1 (ko) | 항염증 활성을 갖는 올리고뉴클레오티드 | |
| Neamțu et al. | The impact of inflammation and drug interactions on covid-19 pharmacotherapy. A mini-review | |
| CN101062066A (zh) | 兽用复方板蓝根注射液及其制备工艺 | |
| US20230277637A1 (en) | Method for the treatment of a viral infection with human alpha-1 antitrypsin | |
| CN114377110A (zh) | 一种化合物rkc-b1在抑制神经炎症方面的用途 | |
| CN111728968A (zh) | 瑞香素在制备治疗银屑病的药物中的应用 | |
| CN115429794B (zh) | 3-甲基吲哚二甲基氨基二硫代酸酯在制备防治牙周炎药物的用途 | |
| Stone | The possible role of mega-ascorbate in the endogenous synthesis of interferon | |
| CN114504588B (zh) | 金黄霉素a制备抑制神经炎症药物中的用途 | |
| CN111214472B (zh) | 依诺沙星在制备预防和/或治疗黄病毒感染的药物中的应用 | |
| Liu et al. | Zingerone attenuates concanavalin A-induced acute liver injury by restricting inflammatory responses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |